Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Moricizine | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Moricizine | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Moricizine | hsa00220 | Arginine biosynthesis | 1.21E-02 | 1 | P15104 | GLUL | More | | Moricizine | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Moricizine | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | | Moricizine | hsa00510 | N-Glycan biosynthesis | 3.15E-02 | 2 | P15907, Q9NR34 | ST6GAL1, MAN1C1 | More | | Moricizine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Moricizine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Moricizine | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Moricizine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Moricizine | hsa00830 | Retinol metabolism | 2.20E-02 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Moricizine | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Moricizine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | Moricizine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Moricizine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Moricizine | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Moricizine | hsa01230 | Biosynthesis of amino acids | 5.53E-03 | 2 | P15104, P37837 | GLUL, TALDO1 | More | | Moricizine | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Moricizine | hsa04064 | NF-kappa B signaling pathway | 9.71E-05 | 15 | P10415, O00463, P14778, P01584, P01375, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, Q13315, P24522, P09341, Q9NQC7 | BCL2, TRAF5, IL1R1, IL1B, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, ATM, GADD45A, CXCL1, CYLD | More | | Moricizine | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | | Moricizine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Moricizine | hsa04140 | Autophagy - animal | 4.55E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Moricizine | hsa04142 | Lysosome | 2.64E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | Moricizine | hsa04145 | Phagosome | 2.59E-02 | 9 | O75015, Q15080, Q99437, P05164, P78380, O60603, P35443, P13765, P25774 | FCGR3B, NCF4, ATP6V0B, MPO, OLR1, TLR2, THBS4, HLA-DOB, CTSS | More | | Moricizine | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Moricizine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | Moricizine | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Moricizine | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | Moricizine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Moricizine | hsa04612 | Antigen processing and presentation | 3.69E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Moricizine | hsa04613 | Neutrophil extracellular trap formation | 4.05E-03 | 18 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, Q93077, P62807, O60814, P68431, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Moricizine | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Moricizine | hsa04625 | C-type lectin receptor signaling pathway | 8.11E-03 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Moricizine | hsa04640 | Hematopoietic cell lineage | 5.76E-03 | 11 | P13612, P14778, P27930, P15144, P11836, P25063, P09693, P01732, P13765, P01375, P01584 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD24, CD3G, CD8A, HLA-DOB, TNF, IL1B | More | | Moricizine | hsa04650 | Natural killer cell mediated cytotoxicity | 1.19E-03 | 10 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Moricizine | hsa04657 | IL-17 signaling pathway | 3.31E-03 | 8 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | Moricizine | hsa04658 | Th1 and Th2 cell differentiation | 2.46E-04 | 10 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765, P23458 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB, JAK1 | More | | Moricizine | hsa04659 | Th17 cell differentiation | 9.35E-04 | 12 | Q04759, Q16539, P06239, P13765, P14778, Q9HBE5, Q9UL17, P23771, P01584, P09693, P20963, P23458 | PRKCQ, MAPK14, LCK, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, IL1B, CD3G, CD247, JAK1 | More | | Moricizine | hsa04660 | T cell receptor signaling pathway | 1.79E-04 | 12 | P01375, Q9UDY8, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Moricizine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Moricizine | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.17E-02 | 8 | P14778, P01584, P51828, P22694, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, MAPK14, ITPR1, PRKCQ, CALM2 | More | | Moricizine | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Moricizine | hsa04912 | GnRH signaling pathway | 4.33E-02 | 6 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB | More | | Moricizine | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Moricizine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Moricizine | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | | Moricizine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Moricizine | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | Moricizine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Moricizine | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | | Moricizine | hsa05140 | Leishmaniasis | 2.50E-03 | 9 | P13612, O75015, P23458, P13765, O60603, P01375, P01584, Q16539, Q15080 | ITGA4, FCGR3B, JAK1, HLA-DOB, TLR2, TNF, IL1B, MAPK14, NCF4 | More | | Moricizine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Moricizine | hsa05144 | Malaria | 8.73E-04 | 6 | P60033, O60603, P01375, P35443, P01584, P26718 | CD81, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Moricizine | hsa05146 | Amoebiasis | 3.00E-03 | 9 | P01584, P09341, P14778, P27930, P01375, O60603, P05089, P22694, P08311 | IL1B, CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | | Moricizine | hsa05152 | Tuberculosis | 4.16E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | Moricizine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Moricizine | hsa05202 | Transcriptional misregulation in cancer | 4.60E-04 | 17 | Q13315, P17844, P14780, P27930, Q15744, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | ATM, DDX5, MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13315 | ATM | Serine-protein kinase ATM | 0.752 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P17844 | DDX5 | Probable ATP-dependent RNA helicase DDX5 | 0.863 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.94 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P14780 | MMP9 | Matrix metalloproteinase-9 | -0.855 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.926 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.727 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q15744 | CEBPE | CCAAT/enhancer-binding protein epsilon | -0.833 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.958 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.877 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.796 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.83 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P35226 | BMI1 | Polycomb complex protein BMI-1 | 0.76 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P35226 | BMI1 | Polycomb complex protein BMI-1 | 0.76 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P05164 | MPO | Myeloperoxidase | 0.719 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P05164 | MPO | Myeloperoxidase | -0.811 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P12838 | DEFA4 | Neutrophil defensin 4 | 0.784 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P12838 | DEFA4 | Neutrophil defensin 4 | -0.86 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08246 | ELA2 | Neutrophil elastase | 0.702 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P08246 | ELA2 | Neutrophil elastase | -0.782 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.783 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | 0.9 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.919 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q92769 | HDAC2 | Histone deacetylase 2 | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P12980 | LYL1 | Protein lyl-1 | 0.784 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.819 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.75 |
| Moricizine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Moricizine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Moricizine | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Moricizine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.10E-02 | 8 | O95267, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539 | RASGRP1, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14 | More | | Moricizine | hsa05310 | Asthma | 1.92E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Moricizine | hsa05321 | Inflammatory bowel disease | 1.72E-05 | 8 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B, IL21R | More | | Moricizine | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Moricizine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Moricizine | hsa05332 | Graft-versus-host disease | 2.50E-03 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | |